JP2024518156A5 - - Google Patents

Info

Publication number
JP2024518156A5
JP2024518156A5 JP2023568023A JP2023568023A JP2024518156A5 JP 2024518156 A5 JP2024518156 A5 JP 2024518156A5 JP 2023568023 A JP2023568023 A JP 2023568023A JP 2023568023 A JP2023568023 A JP 2023568023A JP 2024518156 A5 JP2024518156 A5 JP 2024518156A5
Authority
JP
Japan
Prior art keywords
retention system
gastric retention
extruded portion
extruded
buprenorphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072114 external-priority patent/WO2022236288A1/en
Publication of JP2024518156A publication Critical patent/JP2024518156A/ja
Publication of JP2024518156A5 publication Critical patent/JP2024518156A5/ja
Pending legal-status Critical Current

Links

JP2023568023A 2021-05-05 2022-05-04 ブプレノルフィンとナロキソンを含む胃内滞留システム Pending JP2024518156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184734P 2021-05-05 2021-05-05
US63/184,734 2021-05-05
PCT/US2022/072114 WO2022236288A1 (en) 2021-05-05 2022-05-04 Gastric residence systems comprising buprenorphine and naloxone

Publications (2)

Publication Number Publication Date
JP2024518156A JP2024518156A (ja) 2024-04-25
JP2024518156A5 true JP2024518156A5 (enExample) 2025-05-09

Family

ID=83932451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568023A Pending JP2024518156A (ja) 2021-05-05 2022-05-04 ブプレノルフィンとナロキソンを含む胃内滞留システム

Country Status (8)

Country Link
US (1) US20240252483A1 (enExample)
EP (1) EP4333823A4 (enExample)
JP (1) JP2024518156A (enExample)
CN (1) CN117615754A (enExample)
AU (1) AU2022270752A1 (enExample)
CA (1) CA3217611A1 (enExample)
IL (1) IL308210A (enExample)
WO (1) WO2022236288A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
JP6210988B2 (ja) * 2011-09-19 2017-10-11 オレクソ・アクチエボラゲット オピオイド依存を治療するための新規乱用耐性医薬組成物
US9687445B2 (en) * 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
NZ727659A (en) * 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN109310639A (zh) * 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films

Similar Documents

Publication Publication Date Title
JP2024518156A5 (enExample)
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
CA2628200A1 (en) Solid pharmaceutical compositions containing pregabalin
JP2019523270A (ja) ドネペジル経皮送達システム
BR9711378A (pt) Forma gal-ncia com libera-Æo prolongada
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
HUT74906A (en) Process for producing medical preparations for treatment of neurologic disorders
JP2005503399A5 (enExample)
JP2010518086A5 (enExample)
JP2004506682A5 (enExample)
TW200502008A (en) Patches for mucosa of oral cavity containing fentanyl
RU2004105263A (ru) Фармацевтические композиции, содержащие тербинафин, и их применение
ATE454906T1 (de) Feste zusammensetzung mit einem protonenpumpenhemmer
US11957686B2 (en) Compositions for delivery of reboxetine
JP2008543936A5 (enExample)
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
JP2024517829A5 (enExample)
WO2024073752A3 (en) Risperidone dosage regimens with gastric residence systems
US20210015823A1 (en) Compositions for delivery of reboxetine
NO20070522L (no) Oral vedvarende frigivelsesformulering av tedisamil med gastriske bibeholdelsesegenskaper
WO2012042314A1 (en) Treatment of tinnitus and related auditory dysfunctions
US20170071880A1 (en) Selegiline transdermal system
JP4953673B2 (ja) 経口投与剤
HU229354B1 (en) Buprenorphine for urinary incontinence therapy